BioCardia Announces Pause in Enrollment for Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial

BioCardia Announces Pause in Enrollment for Phase III CardiAMP Cell Therapy Heart Failure Trial SUNNYVALE, Calif., July 24, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for cardiovascular and pulmonary disease treatment, has received a recommendation from the independent Data Safety Monitoring Board (DSMB) to temporarily pause new..

• format_list_bulleted Pharmacology/BS
• · 2023. 7. 24.
• textsms

BioRestorative Therapies' Drug Candidate BRTX-100 Passes Safety Test With Flying Colors, Moves Ahead With Phase 2 And Looks To Expand Pipeline Opportunities

BioRestorative Therapies' drug candidate BRTX-100 has successfully passed a safety test and is now moving forward with its Phase 2 clinical trial. The trial focuses on chronic lumbar disc disease, and the independent review board overseeing the trial has unanimously recommended its continuation without any changes to the protocol. &nbsp This recommendation from the Data Safety Monitoring Board (..

• format_list_bulleted Pharmacology/BS
• · 2023. 7. 10.
• textsms